Stanford



Wen-Kai Weng, MD, PhD

Associate Professor of Medicine (Blood and Marrow Transplantation) and, by courtesy, of Dermatology at the Stanford University Medical Center

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICES

- **Stanford Cancer Center**

  875 Blake Wilbur Dr Clinic F

  MC 6560

  Stanford, CA 94305

  Tel (650) 498-6000 **Fax** (650) 498-6919

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

  Jenny McGuire - Administrative Assistant

  Email jennymcg@stanford.edu

  Tel 650-723-0837

Bio

BIO

Dr. Wen-Kai Weng specializes in the treatment of non-Hodgkin's lymphoma (NHL), his basic research interest is immunotherapy for lymphoma and cancer, with two components: tumor specific targeting therapy and allogeneic transplant. He is currently working on new strategies to target patient-specific tumor using antibody along with effector cells. He is also conducting clinical study looking at the clinical efficacy of allogeneic transplant in patients with cutaneous lymphoma.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Cancer > Lymphoma
- Cutaneous T-Cell Lymphoma
- Medical Oncology
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Immunotherapy

ACADEMIC APPOINTMENTS

- Associate Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Associate Professor - Med Center Line (By courtesy), Dermatology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Scientific Advisory Board, Lymphoma Research Foundation, (2011-2012)
- Co-Director, Stanford Multidisciplinary Cutaneous Lymphoma Clinic, (2014- present)
- Director, CCT/BMT Fellowship Program, (2015- present)

HONORS AND AWARDS

- Predoctoral National Research Service Award, NIH/NIAID (1994-1995)

- Doctoral Dissertation Award, University of Minnesota Graduate School (1995)
- Charles and Dorothy Andrew Bird Award, Sigma Xi Scientific Research Society (1996)
- Fellowship, Lymphoma Research Foundation (2002-2004)
- K08 Clinical Scientist Career Development Award, NIH/NCI (2005-2009)
- Developmental Research Award, Stanford University Cancer Center (2009-2010)
- ITI Seed Grant Award, Institute for Immunity, Transplantation and Infection, Stanford University (2011-2012)
- Developmental Research Award, Stanford Cancer Institute (2012-2013)
- Translational Research Grant, Stanford Cancer Institute (2014-2015)
- Division Teaching Award, BMT, Stanford University (2009, 2010, 2012, 2015, 2016, 2018, 2019)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Co-Director, Stanford Cancer Immunotherapy and Blood & Marrow Transplantation Symposium (2018 - present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University School of Medicine (2002) CA
- Fellowship, Stanford University , Medical Oncology (2002)
- Residency, University of Texas-Houston , Internal Medicine (1999)
- Internship, University of Texas-Houston , Internal Medicine (1997)
- PhD, University of Minnesota , Pathobiology (1996)
- MD, ChungShan Medical and Dental College , Medicine (1988)

PATENTS

- Ronald Levy, Wen-Kai Weng. "United States Patent 9109255 Methods and compositions for determining responsiveness to antibody therapy", Aug 18, 2015

LINKS

- Wen-Kai Weng, MD, PhD: http://www.stanford.edu/~wkweng/weng.home.htm
- Get a Second Opinion: https://stanfordhealthcare.org/second-opinion/overview.html

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My clinical focus is non-Hodgkin's lymphoma (NHL) and am currently conducting clinical trials with novel therapies on these patients. My basic research interest is immunotherapy for lymphoma, with two components: tumor vaccines and allogeneic transplant. For the tumor vaccine, I am working with my colleagues in Oncology to conduct a clinical trial using a CpG-activated tumor vaccine in mantel cell NHL patients who undergo autologous transplantation. The goal is to sensitize the autologous T cells to recognize the malignant lymphoma cells and to expand these tumor-specific T cells immediate after autologous transplant.

Second, I am conducting a study using a novel non-myeloablative preparative regimen prior to allogeneic transplant in patients with mycosis fungoides/Sezary syndrome, a cutaneous T cell NHL. While these patients exhibit little sensitivity to traditional chemotherapy, graft-versus-lymphoma effect provided by allogeneic transplant seems to have an excellent disease control effect. I also use high throughput sequencing technology to assess the minimal residual disease and the immune reconstitution after allogeneic transplant.

CLINICAL TRIALS

- Bone Marrow Grafting for Leukemia and Lymphoma, Recruiting

- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma, Recruiting
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant, Recruiting
- Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation, Recruiting
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma, Recruiting
- Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries, Recruiting
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors, Recruiting
- Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies, Recruiting
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial), Not Recruiting
- A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease, Not Recruiting
- A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1), Not Recruiting
- A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML), Not Recruiting
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802), Not Recruiting
- Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102), Not Recruiting
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML, Not Recruiting
- Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies, Not Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma, Not Recruiting
- Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level, Not Recruiting
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801), Not Recruiting
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment, Not Recruiting
- Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT), Not Recruiting
- Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder, Not Recruiting
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Double Cord Versus Haploidentical (BMT CTN 1101), Not Recruiting
- Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting
- Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies, Not Recruiting
- High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma, Not Recruiting
- Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD, Not Recruiting
- Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT), Not Recruiting
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML, Not Recruiting
- Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma, Not Recruiting
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203), Not Recruiting
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201), Not Recruiting
- Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD, Not Recruiting
- Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell, Not Recruiting

- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL, Not Recruiting
- Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT, Not Recruiting
- Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG, Not Recruiting
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders, Not Recruiting
- Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma, Not Recruiting
- Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT, Not Recruiting
- Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702), Not Recruiting
- Targeted Therapy of Bronchiolitis Obliterans Syndrome, Not Recruiting
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD, Not Recruiting
- Transplantation for Patients With Chronic Lymphocytic Leukemia, Not Recruiting
- Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma, Not Recruiting

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Jay Spiegel

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
  Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
  2020; 217 (9)

- **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*
  Weng, W. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., Shizuru, J., Muffly, L., Meyer, E., Negrin, R. S., Wang, E., Almazan, T., Million, et al
  2020; 4 (18): 4474–82

- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*
  Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M., Negrin, R., Weng, W. K., Meyer, E., Shizuru, et al
  2020

- **Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs** *PRACTICAL RADIATION ONCOLOGY*
  Obeid, J., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., Kim, Y. H., Weng, W., Hoppe, R. T., Hiniker, S. M.
  2019; 9 (4): 220–25

- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*
  Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al
  2019; 4 (10)

- **Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients.** *Clinical case reports*
  Wang, J. Y., Tabata, M. M., Pugliese, S., Phillips, D., Kim, J., Weng, W. K., Kwong, B. Y.
  2019; 7 (12): 2491–94

- **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
  Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al
  2019; 3 (16): 2454–64

- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
  Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
  2018; 2 (6): 681–90

- **Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.** *JAMA dermatology*
  Dai, J., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S., Weng, W. K., Kim, Y. H.
  2018

- **Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
  Kuklinski, L. F., Li, S., Karagas, M. R., Weng, W., Kwong, B. Y.
  2017; 77 (4): 706–12

- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
  2017; 23 (10): 1744–48

- **Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.** *Journal of cutaneous pathology*
  Cedeno-Laurent, F., Wysocka, M., Obstfeld, A. E., Novoa, R. A., Vittorio, C. C., Kim, E. J., Weng, W., Rook, A. H.
  2017

- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
  Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al
  2017; 1 (17): 1347–57

- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*
  Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al
  2015; 33 (32): 3750-3758

- **Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.** *Nature genetics*
  Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., Zehnder, A., Ohgami, R., Kulkarni, S., Armstrong, R., Weng, W., Gratzinger, D., Tavallaee, et al
  2015; 47 (9): 1056-1060

- **Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.** *Biology of blood and marrow transplantation*
  Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.
  2014; 20 (6): 837-843

- **European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation** *BLOOD CANCER JOURNAL*
  Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., Shizuru, J. A., Miklos, D. B., Arai, S., Benjamin, J. E., Weng, W., Negrin, R. S., Lowsky, R.
  2014; 4

- **Cancer Vaccines and T Cell Therapy** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., Weng, W., Negrin, R. S., Carlton, V., Faham, M., Levy, R., Barrett, J.

2013; 19 (1): S97-S101

- **Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma** *SCIENCE TRANSLATIONAL MEDICINE*

  Weng, W. K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., Kim, Y. H.

  2013; 5 (214): 214ra171

- **Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence** *BLOOD*

  Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., Shizuru, J. A., Johnston, L. J., Laport, G. G., Weng, W., Benjamin, J. E., Schaenman, J., Brown, et al

  2012; 119 (25): 6145-6154

- **The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients** *AMERICAN JOURNAL OF HEMATOLOGY*

  Kelly-Sell, M. J., Kim, Y. H., Straus, S., Benoit, B., Harrison, C., Sutherland, K., Armstrong, R., Weng, W., Showe, L. C., Wysocka, M., Rook, A. H.

  2012; 87 (4): 354-360

- **Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma** *BONE MARROW TRANSPLANTATION*

  Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., Miklos, D. B., Arai, S., Weng, W., Laport, G. G., Stockerl-Goldstein, K.

  2012; 47 (4): 516-521

- **Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts** *BLOOD*

  Lee, C. S., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D. E., Armstrong, R., Weng, W. K., Aros, C. J., Mah, A., Chen, R. O., Lin, M., Sundram, U., Chang, et al

  2012; 120: 3288-3297

- **Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*

  Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., Johnston, L. J., Shizuru, J. A., Miklos, D., Arai, S., Benjamin, J. E., Weng, W., Negrin, et al

  2011; 17 (11): 1679-1687

- **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*

  Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al

  2010; 16 (8): 1145-1154

- **The IgG Fc Receptor Fc#RIIIa 158 V/F Polymorphism is Correlated with Rituximab-Induced Neutropenia after Autologous Transplantation in Patients with Non-Hodgkin Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*

  Weng, W. K., Negrin, R., Lavori, P., Horning, S. J.

  2010; 28: 279-284

- **TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors** *BLOOD*

  Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., Johnston, L. J., Arai, S., Weng, W., Hoppe, R. T., Lavori, P. W., Blume, K. G., Negrin, et al

  2009; 114 (5): 1099-1109

- **Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma** *LEUKEMIA & LYMPHOMA*

  Timmerman, J. M., Vose, J. M., Czerwinski, D. K., Weng, W., Ingolia, D., Mayo, M., Denney, D. W., Levy, R.

  2009; 50 (1): 37-46

- **Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab** *LEUKEMIA & LYMPHOMA*

  Weng, W. K., Levy, R.

  2009; 50 (5:723-727)

- **Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or Clinical Course in Patients with Follicular Lymphoma** *LEUKEMIA & LYMPHOMA*

Weng, W. K., Levy, R.
2009; 50 (9): 1494-1500

- **A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma** *CLINICAL CANCER RESEARCH*
  Racila, E., Link, B. K., Weng, W., Witzig, T. E., Ansell, S., Maurer, M. J., Huang, J., Dahle, C., Halwani, A., Levy, R., Weiner, G. J.
  2008; 14 (20): 6697-6703

- **The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells** *BLOOD*
  Luqman, M., Klabunde, S., Lin, K., Georgakis, G. V., Cherukuri, A., Holash, J., Goldbeck, C., Xu, X., Kadel, E. E., Lee, S. H., Aukerman, S. L., Jallal, B., Aziz, et al
  2008; 112 (3): 711-720

- **Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless their response to induction chemotherapy.** *BLOOD*
  Weng, W. K., Czerwinski , D., Levy, R.
  2007; 109: 951-3

- **Immune-mediated antitumor effects with antibody therapy.** *American Society of Clinical Oncology Educational Book*
  Weng WK
  2005: 200-4

- **Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.** *JOUNRAL OF CLINICAL ONCOLOGY*
  Weng, W. K., Czerwinski , D., Timmerman, J., Hsu, F. J., Levy, R.
  2004; 22: 4717

- **Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
  Weng, W. K., Levy, R.
  2003; 21 (21): 3940-3947

- **Hepatitis C virus (HCV) and lymphomagenesis** *LEUKEMIA & LYMPHOMA*
  Weng, W. K., Levy, S.
  2003; 44 (7): 1113-1120

- **Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma** *BLOOD*
  Weng, W. K., Levy, R.
  2001; 98 (5): 1352-1357

- **Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells** *JOURNAL OF IMMUNOLOGY*
  Weng, W. K., Shah, N., O'Brien, D., Van Ness, B., LeBien, T. W.
  1997; 159 (11): 5502-5508

- **SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS** *JOURNAL OF BIOLOGICAL CHEMISTRY*
  Weng, W. K., Jarvis, L., LeBien, T. W.
  1994; 269 (51): 32514-32521

- **FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS** *JOURNAL OF IMMUNOLOGY*
  Wolf, M. L., Weng, W. K., STIEGLBAUER, K. T., Shah, N., LeBien, T. W.
  1993; 151 (1): 138-148